Boston Interactome
Boston Interactome provides a platform that generates high-quality empirical data on protein-protein interactions (PPIs) directly in cells, enabling the design of therapies that target only pathogenic pathways while preserving normal cellular functions. Their in-cellulo detection technology offers several-fold higher sensitivity than competing methods, with extensive internal controls to minimize false positives while maintaining throughput.
- Drug Discovery & Therapeutics
- Biotechnology
Funding
Founders
Founder details are not available yet.
Product
Problem
95% of approved medicines target proteins as isolated entities, bluntly turning them on or off. This modulates protein function globally, across both pathogenic and healthy cellular pathways, which is why essentially all medicines come with side effects.
Solution
Boston Interactome targets protein-protein interactions (PPIs) rather than individual proteins, aiming to modulate only the pathogenic pathway while leaving healthy functions intact. Their platform is purpose-built for high-quality empirical PPI data generation, quantifying PPIs directly in cells via diverse detection modes that surface highly transient interactions with rich biological context. The technology incorporates large internal controls to minimize false positives and negatives, achieving several-fold higher PPI detection sensitivity than any other in-cellulo PPI detection technology without sacrificing throughput. This enables the design of safer, more targeted medicines that preserve normal cellular functions.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing targeted therapies who need high-quality empirical PPI data to design medicines that modulate only pathogenic pathways while preserving healthy cellular functions.
Features
- In-cellulo detection: quantifies PPIs directly in cells via diverse detection modes, surfacing highly transient interactions with rich biological context
- High signal-to-noise ratio: large internal controls minimize false positives and negatives
- Exceptional data quality: several-fold higher PPI detection sensitivity than any other in-cellulo PPI detection technology, without sacrificing throughput
- Platform purpose-built for high-quality empirical PPI data generation to support targeted therapy design